Want to see JP:2796 full AI Analyst Report?
2796 Stock Chart & Stats
¥521.00
-¥5.00(-0.91%)
At close: 4:00 PM EST
¥521.00
-¥5.00(-0.91%)
Day’s Range― - ―
52-Week Range¥474.00 - ¥558.00
Previous CloseN/A
Volume3.80K
Average Volume (3M)15.55K
Market Cap
¥5.71B
Enterprise Value¥18.21B
Total Cash (Recent Filing)¥2.12B
Total Debt (Recent Filing)¥13.03B
Price to Earnings (P/E)47.2
Beta0.19
Next Earnings
Oct 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.65%
Share Statistics
EPS (TTM)-22.36
Shares Outstanding12,060,381
10 Day Avg. Volume9,170
30 Day Avg. Volume15,546
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)0.85
Price to Sales (P/S)0.08
P/FCF Ratio2.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthRevenue expansion from ~52.3B in 2021 to ~69.5B in 2026 shows durable top-line momentum. Persistent sales growth supports scale economics, market positioning and reinvestment capacity, underpinning longer-term recovery in operating margins and funding for R&D or market expansion.
Strong Cash GenerationOperating cash flow rose sharply to ~3.28B and free cash flow to ~2.58B in 2026, indicating reliable cash conversion even when earnings were volatile. Sustainable cash generation enhances funding for capex, dividends and debt reduction, reducing dependence on external financing and supporting strategic flexibility.
Meaningful Debt ReductionA large decline in total debt (to ~5.3B in 2026 from ~14.3B) materially lowers interest and refinancing pressure. Improved leverage increases balance-sheet optionality for M&A, R&D investment or shareholder returns, and enhances resilience to revenue or margin fluctuations over the medium term.
Bears Say
Inconsistent ProfitabilityThe company had losses in 2024–2025 and only a very small profit in 2026 (~0.11B on ~69.5B revenue), reflecting highly inconsistent profitability. Persistent thin net margins signal structural sensitivity to cost, pricing or mix, limiting predictability of durable earnings and reinvestment capacity.
Limited Equity GrowthEquity has stayed roughly flat (~6.8B) despite asset growth, so the capital base has not expanded meaningfully. A muted equity cushion constrains the firm’s ability to absorb shocks, increasing reliance on cash flow and limiting room for sustained leverage or investment without risking solvency under stress.
Historic Elevated Leverage & VolatilityPrior years featured elevated leverage (debt-to-equity >2.0x in 2025) and material swings in operating profitability. That history raises refinancing and solvency risks during downturns; recent debt cuts help, but the structural risk from past high leverage and earnings volatility remains a durable constraint on financial stability.
Pharmarise Holdings Corp. News
2796 FAQ
What was Pharmarise Holdings Corp.’s price range in the past 12 months?
Pharmarise Holdings Corp. lowest stock price was ¥474.00 and its highest was ¥558.00 in the past 12 months.
What is Pharmarise Holdings Corp.’s market cap?
Pharmarise Holdings Corp.’s market cap is ¥5.71B.
When is Pharmarise Holdings Corp.’s upcoming earnings report date?
Pharmarise Holdings Corp.’s upcoming earnings report date is Oct 08, 2026 which is in 99 days.
How were Pharmarise Holdings Corp.’s earnings last quarter?
Pharmarise Holdings Corp. released its earnings results on Jun 25, 2026. The company reported -¥13.44 earnings per share for the quarter, missing the consensus estimate of N/A by -¥13.44.
Is Pharmarise Holdings Corp. overvalued?
According to Wall Street analysts Pharmarise Holdings Corp.’s price is currently Overvalued.
Does Pharmarise Holdings Corp. pay dividends?
Pharmarise Holdings Corp. pays a Annually dividend of ¥14 which represents an annual dividend yield of 2.65%. See more information on Pharmarise Holdings Corp. dividends here
What is Pharmarise Holdings Corp.’s EPS estimate?
Pharmarise Holdings Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharmarise Holdings Corp. have?
Pharmarise Holdings Corp. has 12,060,381 shares outstanding.
What happened to Pharmarise Holdings Corp.’s price movement after its last earnings report?
Pharmarise Holdings Corp. reported an EPS of -¥13.44 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.165%.
Which hedge fund is a major shareholder of Pharmarise Holdings Corp.?
Currently, no hedge funds are holding shares in JP:2796
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pharmarise Holdings Corp.
Pharmarise Holdings Corporation predominantly oversees a chain of pharmacies that dispense prescription medications throughout Japan. These establishments fulfill prescriptions provided by medical facilities, offering vital pharmaceutical services to patients. Beyond its primary dispensing activities, the company also manages drugstores and convenience stores, and retails cosmetic products. Additionally, it provides services including the safekeeping and administration of patient medical records for healthcare institutions, operates medical complex centers, and offers temporary staffing assistance. As of May 31, 2021, the corporation maintained a network of 347 outlets. Pharmarise Holdings Corporation was founded in 1984 and its main office is located in Tokyo, Japan.
Technical Analysis
Ohki Health Care Holdings, Inc.
―
Medical System Network Co., Ltd.
―
Shinnihonseiyaku Co., Ltd.
―
Chordia Therapeutics Inc.
―
Heartseed, Inc.
―